Manulife Financial Corporation announced on February 11, 2026, that it intends to launch a Normal Course Issuer Bid (NCIB), subject to approval by the Toronto Stock Exchange. The proposed NCIB, approved by the Office of the Superintendent of Financial Institutions (Canada), would permit the purchase for cancellation of up to 42 million common shares, representing approximately 2.5% of the 1,676,743,043 common shares outstanding as at January 31, 2026.

The NCIB is designed to support Manulife’s capital management strategy by maintaining regulatory capital ratios while balancing the goal of generating shareholder value. Purchases under the NCIB may be made through the facilities of the Toronto Stock Exchange, the New York Stock Exchange, or alternative trading systems in Canada and the United States at prevailing market prices, or as otherwise permitted by applicable regulations.

Manulife’s previous NCIB began on February 24, 2025, for the purchase of up to 51.5 million common shares. Between the commencement of that bid and January 22, 2026, the company completed the purchase of 51.5 million common shares at a volume weighted average purchase price of C$44.28. All purchased shares were cancelled through facilities of the Toronto Stock Exchange.

In connection with possible future share repurchases, the announcement advises that Manulife may make purchases under private agreements, derivative transactions, or other permitted methods in compliance with applicable regulations. All common shares acquired under the NCIB will be cancelled, and the total number of shares purchased under any related arrangements will not exceed 42 million.

The announcement includes caution that forward-looking statements related to future share purchases entail risks and uncertainties. Factors such as earnings, cash requirements, market conditions, capital requirements, and regulatory approvals may affect the timing and extent of share repurchases.

Manulife is a leading international financial services provider, operating primarily as Manulife across Canada, Asia, and Europe, and as John Hancock in the United States. At the end of 2024, it reported more than 37,000 employees, over 109,000 agents, and millions of customers worldwide. The company trades under the ticker “MFC” on the Toronto, New York, and Philippine stock exchanges and “945” in Hong Kong.